The bioavailability of ultramicrosize griseofulvin (Gris-Peg) tablets in man
Barrett, W.E.; Bianchine, J.R.
Current Therapeutic Research 18(3): 501-509
In an effort to provide for a better absorption and a more predictale blood level of griseofulvin, the drug was incorporated into a PEG;6000 formulation. This ultramicrosize formulation (called Gris-PEG® tablets) was compared to commercially available microsize griseofulvin in normal male volunteers. The two studies reported were a double-blind, single-dose, parallel-group design and a crossover design. The results derived from these two studies indicate that the oral absorption of griseofulvin, in man, is significantly enhanced by the PEG formulation since essentially the same plasma levels were achieved with 250 mg. of the ultramicrosize griseofulvin (Gris-PEG®) as were achieved with a 500-mg. dose. of the marketed microsize form of griseofulvin. The bioavailability of 250 mg. of the ultramicrosize griseofulvin was equivalent to that of a 500-mg. dose of the microsize formulation.